The US FDA has approved a petition submitted by Ingredion, resulting in a qualified health claim that will enable food manufacturers to communicate the relationship between high-amylose maize resistant starch and a reduced risk of Type 2 diabetes on the packages of conventional foods.###In reviewing Ingredion’s petition, the FDA concluded that there was scientific evidence for a qualified health claim for high-amylose maize rfersamalesistant starch and reduced risk ofmagnesium citrate for what Type 2 diabetes, while ensuring thmagnesium lactate in foode claim was appropriately worded so as not to be misleading:###· High-amylose maize resistant starch may reduce the risk of Type 2 diabetes. FDA has concluded that there is limited scientimag citrate liquid laxativefic evidence for this claim.###· High-amylose maize resistant starch, a type of fiber, may reduce the risk of Type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim.###These claims can becitracal maximum calcium citrate used on the packaging of conventional foods, as defined by 21 CFR 101.14. ###Such products include bakery items, nutrition bars, cereals and pastas among others.###The qualified health claim petition was based on eight clinical trials conducted at academic institutions and research organizations, which assessed the impact of Hi-Maize high-amylose maize resistant starch on insulin sensitivity and other biomarkers. ###Hi-Maize resistant starch is a type of dietary fiber derived from a variety of corn that is high in amylose starch.###It is a white powder with a mild taste that is easily incorporated into everyday foods.